ReviewJHEP reports : innovation in hepatology2024
Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
Review in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting Myosteatosis Though Physical Exercise to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
MYO-SLD : a Prospective Study to Determine the Phenotype of Muscle Fat Accumulation in a Cohort of Patients With SLD as to Confirm the Association Between Muscle Composition and Texture and the Phenotype of Liver Disease
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.PloS one · 2024Pooled it
- Changes in Muscle Mass and the Risk of Liver-Related Events: A Prospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes.Journal of gastroenterology · 2026Article
- Review
- Sarcopenia Predicts Mortality and Hepatic Encephalopathy After TIPS in Older Adults With Cirrhosis and Improves Prognostic Scores.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Pathological changes and therapeutic strategies for sarcopenia.EFORT open reviews · 2026Review
- Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules · 2026Review
- Applications of bioimpedance measurement in clinical and allied fields: a comprehensive review.Biomedical engineering online · 2026Review
- Low muscle mass predicts liver-related outcomes in cirrhosis, independent of portal hypertension: A retrospective cohort study.Canadian liver journal · 2026Article
- Chronicity and physical activity levels independently associate with spatial patterns of multifidus fat infiltration in chronic low back pain patients.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Muscle ultrasonography in costello syndrome: unveiling new clinical insights of a complex muscular phenotype.Orphanet journal of rare diseases · 2026Article
- Review
- Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets.Frontiers in endocrinology · 2026Review
- Prognostic Value of Chest CT-Derived Pectoralis Muscle Metrics for In-Hospital Mortality and Invasive Mechanical Ventilation in AECOPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Celery seed extract attenuates sarcopenic obesity and age-related sarcopenia by reducing intramuscular lipid accumulation in mice.Frontiers in nutrition · 2026Article
- Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs.Korean journal of radiology · 2026Review
- DNA2 acts as a brake on β cell insulin hypersecretion and diet-induced metabolic dysfunction.Frontiers in cell and developmental biology · 2026Article
- Adipose-muscle crosstalk during the menopausal transition: mechanistic links to sarcopenic obesity in midlife women.Frontiers in endocrinology · 2026Review
- The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with an increased risk of multisystemic complications, including muscle changes such as sarcopenia and myosteatosis that can reciprocally affect liver function. We conducted a systematic review to highlight innovative assessment tools, pathophysiological mechanisms and metabolic consequences related to myosteatosis in MASLD, based on original articles screened from PUBMED, EMBASE and COCHRANE databases. Forty-six original manuscripts (14 pre-clinical and 32 clinical studies) were included. Microscopy (8/14) and tissue lipid extraction (8/14) are the two main assessment techniques used to measure muscle lipid content in pre-clinical studies. In clinical studies, imaging is the most used assessment tool and included CT (14/32), MRI (12/32) and ultrasound (4/32). Assessed muscles varied across studies but mainly included paravertebral (4/14 in pre-clinical; 13/32 in clinical studies) and lower limb muscles (10/14 in preclinical; 13/32 in clinical studies). Myosteatosis is already highly prevalent in non-cirrhotic stages of MASLD and correlates with disease activity when using muscle density assessed by CT. Numerous pathophysiological mechanisms were found and included: high-fat and high-fructose diet, dysregulation in fatty acid transport and ketogenesis, endocrine disorders and impaired microRNA122 pathway signalling. In this review we also uncover several potential consequences of myosteatosis in MASLD, such as insulin resistance, MASLD progression from steatosis to metabolic steatohepatitis and loss of muscle strength. In conclusion, data on myosteatosis in MASLD are already available. Screening for myosteatosis could be highly relevant in the context of MASLD, considering its correlation with MASLD activity as well as its related consequences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.